Recruitment

Recruitment Status
Completed

Inclusion Criterias

Serums from patients with ILD: before treatment and 30-90 days after treatment
Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health
Serums from patients with ILD: before treatment and 30-90 days after treatment
Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health

Exclusion Criterias

Serums with floc
Serums from patients with cancer
Serums with visible precipitate
Serums with floc
Serums from patients with cancer
Serums with visible precipitate

Summary

Conditions
Interstitial Lung Disease
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Retrospective

Participation Requirements

Age
Between 14 years and 90 years
Gender
Both males and females

Description

As a multi-center, double-blind clinical study, the trial is divided into two parts. Part 1: The purpose of this part is to evaluate the role of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them...

As a multi-center, double-blind clinical study, the trial is divided into two parts. Part 1: The purpose of this part is to evaluate the role of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases, including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and healthy control group. Part 2: The purpose of this part is to study the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and 30-90 days after treatment. Treatment includes anti fibrosis, anti-inflammatory and other conventional therapies.

Inclusion Criterias

Serums from patients with ILD: before treatment and 30-90 days after treatment
Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health
Serums from patients with ILD: before treatment and 30-90 days after treatment
Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health

Exclusion Criterias

Serums with floc
Serums from patients with cancer
Serums with visible precipitate
Serums with floc
Serums from patients with cancer
Serums with visible precipitate

Tracking Information

NCT #
NCT02197364
Collaborators
Fujirebio Diagnostics, Inc.
Investigators
  • Principal Investigator: Li Hui Ping Shanghai Pulmonary Hospital , Tongji University
  • Li Hui Ping Shanghai Pulmonary Hospital , Tongji University